New stock news | Acrobiosystems (301080.SZ) plans to go public in Hong Kong, with revenue exceeding 600 million yuan in the first three quarters.

On October 29th, Acrobiosystems (301080.SZ) announced that, in order to further promote its internationalization strategy, the company plans to issue shares overseas (H-shares) and list on the Hong Kong Stock Exchange. The company's board of directors has agreed to authorize management to begin the preliminary preparations for this H-share issuance and listing. As of now, the details of this H-share issuance and listing have not been finalized. According to information, Acrobiosystems focuses on the biotechnology field, with main business activities including research, production, and sales of biopharmaceuticals, aiming to provide high-quality bioproducts and services to the medical industry. Additionally, the company is also involved in innovative applications of biotechnology. The company's main products and services are used in drug discovery and validation for diseases such as cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, drug screening and optimization, diagnostic reagent development and optimization, preclinical and clinical trials, and drug production processes and process control (CMC) in the research and production phases. Acrobiosystems' third-quarter report for 2025 shows that the company's operating income for the first three quarters was 6.13 billion yuan, an increase of 32.3% year-on-year; net profit attributable to shareholders was 1.32 billion yuan, an increase of 58.6% year-on-year; non-GAAP net profit attributable to shareholders was 1.33 billion yuan, an increase of 58.8% year-on-year; net cash flow from operations was 1.77 billion yuan, an increase of 99.5% year-on-year; EPS (fully diluted) was 0.789 yuan.